title: Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues.
abstract: 2(1H)-Pyrimidinone riboside (zebularine, 1b) and its 5-fluoro (6b) and 2'-ara-fluoro (7b) analogues have been synthesized and evaluated in vivo as antitumor agents. Zebularine provides increase in life span (ILS) values of ca. 70% against intraperitoneal (ip) murine B16 melanoma and 50% against P388 leukemia. This compound is active when administered either ip or orally against ip or subcutaneously implanted L1210 leukemia, producing ILS values of about 100% at an optimum dose of 400 mg/kg. 1b is also active (60% ILS) against ara-C-resistant L1210. The analogous unsubstituted purine riboside nebularine (2) has modest activity against P388 leukemia (60% ILS). While 2'-ara-fluorozebularine (7b) is only marginally active (40% ILS) at high doses against L1210 leukemia, 5-fluoro analogue 6b is more active than zebularine and is ca. 100 times more potent. Although the activity of 6b is about the same as that of 1b against P388 leukemia, greater potency also is realized in this model. Zebularine is a strong inhibitor of cytidine deaminase, but in contrast to tetrahydrouridine, 1b is acid-stable. In an attempt to use this property to advantage in oral administration, 1b and ara-C have been orally coadministered to mice with ip L1210 leukemia. When zebularine is given in divided doses, up to a 2-fold increase in activity is realized, relative to treatment with the same dose of ara-C alone.
authors.affiliation: Laboratory of Medicinal Chemistry, DTP, DCT, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
authors.forename: J S
authors.initials: JS
authors.lastname: Driscoll
authors.forename: V E
authors.initials: VE
authors.lastname: Marquez
authors.forename: J
authors.initials: J
authors.lastname: Plowman
authors.forename: P S
authors.initials: PS
authors.lastname: Liu
authors.forename: J A
authors.initials: JA
authors.lastname: Kelley
authors.forename: J J
authors.initials: JJ
authors.lastname: Barchi
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000627:therapeutic use; D001087:Arabinonucleosides / Q000138:chemical synthesis* / Q000627:therapeutic use; D003562:Cytidine / Q000031:analogs & derivatives; D004354:Drug Screening Assays, Antitumor; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007939:Leukemia L1210 / Q000188:drug therapy; D007941:Leukemia P388 / Q000188:drug therapy; D051379:Mice; D011741:Pyrimidine Nucleosides / Q000138:chemical synthesis* / Q000627:therapeutic use; D011744:Pyrimidinones / Q000138:chemical synthesis* / Q000627:therapeutic use; D013329:Structure-Activity Relationship
chemical_list: D000970:Antineoplastic Agents; D001087:Arabinonucleosides; D011741:Pyrimidine Nucleosides; D011744:Pyrimidinones; C071838:2'-arafluorozebularine; D003562:Cytidine; C059356:5-fluoropyrimidin-2-one beta-ribofuranoside; C009131:pyrimidin-2-one beta-ribofuranoside